ClinicalTrials.Veeva

Menu

A Trial in Healthy Female Subjects to Compare the Pharmacokinetics of Ethinyl Estradiol of NuvaRing®, a Contraceptive Patch (EVRA(TM)) and an Oral Contraceptive (Microgynon® 30) (Study 34237 (P06650)) (COMPLETED)

Organon logo

Organon

Status and phase

Completed
Phase 4

Conditions

Contraception

Treatments

Drug: norelgestrominum and ethinylestradiol patch oral contraceptive patch
Drug: Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets
Drug: Nuvaring ™ (etonorgestrel/ethinylestradiol)

Study type

Interventional

Funder types

Industry

Identifiers

Details and patient eligibility

About

An open-label, randomized, parallel group trial in healthy female subjects to compare the pharmacokinetics of ethinyl estradiol (EE) of NuvaRing®, a contraceptive patch (EVRA(TM)) and an oral contraceptive (Microgynon® 30).

Enrollment

24 patients

Sex

Female

Ages

18 to 40 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subject is at least 18 but not older than 40 years of age on Day 1 of treatment.
  • Subject has uterus and ovaria in situ
  • Subject who does not use hormonal contraception and is willing to use adequate nonhormonal contraceptive measures during the timeframe between screening and start treatment.
  • Subject is able and willing to refrain from caffeine and/or xanthine containing food and/or beverages (e.g. coffee, tea, cola or chocolate) from 24 hours before the first administration of the trial medication until the last PK blood sample.
  • Subject is willing not to consume grapefruit containing products 14 days prior to the start of the first administration of the trial medication until the last PK blood sample.
  • Subject is willing to refrain from smoking from 7 days prior to first administration of the trial medication until the last pharmacokinetic blood sample.
  • Subject is willing to refrain from alcohol containing products from 24 hours prior to first administration of the trial medication until the last pharmacokinetic blood sample.

Exclusion criteria

  • Contraindications for use of NuvaRing, contraceptive patch and oral contraceptive:
  • Presence or history of venous thrombosis, with or without the involvement of pulmonary embolism.
  • Presence or history of arterial thrombosis (e.g. cerebrovascular accident, myocardial infarction) or prodromi of a thrombosis (e.g. angina pectoris or transient ischaemic attack).
  • Known predisposition for venous or arterial thrombosis, with or without hereditary involvement such as Activated Protein C (APC) resistance, antithrombin-III deficiency, protein C deficiency, protein S deficiency, hyperhomocysteinaemia, antiphospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant) and Factor V Leiden mutation.
  • Diabetes mellitus with vascular involvement
  • The presence of a severe or multiple risk factor(s) for venous or arterial thrombosis (to be judged by the (sub-) investigator
  • Presence or history of severe hepatic disease as long as liver function values had not returned to normal or were judged to be clinically significant by the investigator.
  • Presence or history of liver tumours (benign or malignant).
  • Known or suspected malignant conditions of the genital organs or the breasts, if sex-steroid-influenced.
  • Undiagnosed vaginal bleeding.
  • Hypersensitivity to the active substances or to any of the excipients of NuvaRing, contraceptive patch and oral contraceptive.
  • Migraine with focal aura
  • Known or suspected pregnancy
  • Breastfeeding, or within 2 months after stopping breastfeeding on the day preceding the first administration of trial medication (Day -1).
  • Clinically significant abnormal laboratory, ECG (electrocardiogram) vital signs, physical and gynecological findings at screening.
  • A significant (history of) allergic or other serious disease, particularly gastrointestinal tract disease.
  • Smoking more than 5 cigarettes or 1 pipe or 1 cigar per day for a period of at least 3 months prior to screening.
  • Using any systemic medication (including over the counter (OTC) medication) during the 14 days prior to the day preceding the first administration of trial medication (Day -1), except for oral contraceptive used for synchronization and occasional Ibuprofen.
  • Used any drug or substance that is known to induce drug-metabolizing enzymes within two months prior to the start of synchronization.
  • Received a contraceptive by injection, an implant or hormonal intra-uterine device within 6 months of the day preceding the first administration of trial medication (Day -1), or a hormonal implant or hormonal intra-uterine device removed within 6 months of the day preceding the first administration of trial medication (Day -1).
  • Participated in a drug trial and was administered an investigational drug during the 90 days prior to start of synchronization.
  • Donated blood during the 90 days prior to the day preceding the first administration of trial medication (Day -1).
  • History (within the last 2 years) of excessive alcohol use, use of solvents or of drug abuse.
  • Positive drug test at screening and/or admission (Day -1), or a positive alcohol test at admission (Day -1).
  • Clinically significant abnormal cervical smear result (papaninecolaou (PAP) III or higher) at screening.
  • Acute or chronic hepatitis B/C or human immune deficiency virus (HIV) 1&2 infection.

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

24 participants in 3 patient groups

Levonorgestrel/ethinylestradiol oral contraceptive pill
Active Comparator group
Description:
Microgynon(R), 1 tablet every day for 21 days; each tablet contains 0.150 mg levonorgestrel (LNG) and 0.030 mg ethinylestradiol (EE).
Treatment:
Drug: Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets
Norelgestrominum and ethinylestradiol contraceptive patch
Active Comparator group
Description:
Evra(TM), One patch applied on lower abdomen for 7 days for 3 consecutive weeks, 3 patches in total. Each patch contains 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
Treatment:
Drug: norelgestrominum and ethinylestradiol patch oral contraceptive patch
Etonogestrel and ethinylestradiol contraceptive vaginal ring
Active Comparator group
Description:
Nuvaring(R), Place the ring in the vagina for 21 days, remove for one week. Repeat with new Ring. Dose: per ring 11.7 mg ENG and 2.7 mg EE releasing a daily average amount of 0.120 mg ENG and 0.015 mg EE.
Treatment:
Drug: Nuvaring ™ (etonorgestrel/ethinylestradiol)

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems